Spontaneous remission and clonal evolution in lenalidomide associated secondary AML

Leuk Lymphoma. 2020 Jul;61(7):1724-1727. doi: 10.1080/10428194.2020.1725504. Epub 2020 Feb 20.

Authors

Daniel D Waller¹, Yury Monczak², René P Michel³, Chaim Shustik¹, Michael Sebag¹

Affiliations

¹ Department of Medicine, Division of Hematology, McGill University, Montreal, Canada.
² Department of Pathology, Jewish General Hospital, Montreal, Canada.
³ Department of Pathology, McGill University, Montreal, Canada.

PMID: 32077352
DOI: 10.1080/10428194.2020.1725504

No abstract available

Publication types

Letter

MeSH terms

Clonal Evolution / genetics
Humans
Lenalidomide / adverse effects
Leukemia, Myeloid, Acute* / diagnosis
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / genetics
Neoplasm Recurrence, Local*
Remission Induction
Remission, Spontaneous

Substances

Lenalidomide